Search

Your search keyword '"Cottalorda, J."' showing total 537 results
Start Over Author "Cottalorda, J."
537 results on '"Cottalorda, J."'

1. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

Author

Dimeglio, Chloé, Raymond, Stéphanie, Nicot, Florence, Jeanne, Nicolas, Carcenac, Romain, Lefebvre, Caroline, Izopet, Jacques, Roussel, C, Guillou-Guillemette, H Le, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Si-Mohammed, A, Santos, G Dos, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Jeulin, H, Ferré, V, Rodallec, A, Guen, L Le, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Bouviers-Alias, M, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Soulié, C, Wirden, M, Morand-Joubert, L, Lambert-Niclot, S, Fofana, D, Delaugerre, C, Chaix, ML, Mahjoub, N, Amiel, C, Schneider, V, Giraudeau, G, Beby-Defaux, A, Brodard, V, Maillard, A, Plantier, JC, Mourez, T, Leoz, M, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, and Costagliola, D

Subjects
Clinical Research, Genetics, HIV/AIDS, Infectious Diseases, Infection, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genome, Viral, Genotype, HIV Infections, HIV-1, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation, Rilpivirine, Treatment Outcome, Viral Load, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

ObjectivesTo determine how the load of rilpivirine-resistant variants (mutational load) influences the virological response (VR) of HIV-1-infected patients to a rilpivirine-based first-line regimen.Patients and methodsFour hundred and eighty-nine patients infected with HIV-1 whose reverse transcriptase gene had been successfully resistance genotyped using next-generation sequencing were given a first-line regimen containing rilpivirine. Variables associated with the VR at 12 months were identified using a logistic model. The results were used to build a multivariate model for each mutational load threshold and the R2 variations were analysed to identify the mutational load threshold that best predicted the VR.ResultsThe mutational load at baseline was the only variable linked to the VR at 12 months (P  1700 copies/mL and to 50% when the mutational load was > 9000 copies/mL. The threshold of 9000 copies/mL was associated with the VR at 12 months with an OR of 36.7 (95% CI 4.7-285.1). The threshold of 1700 copies/mL was associated with the VR at 12 months with an OR of 7.2 (95% CI 1.4-36.8).ConclusionsThere is quantifiable evidence that determining a mutational load threshold can be used to identify those patients on a first-line regimen containing rilpivirine who are at risk of virological failure. The clinical management of HIV-infected patients can be improved by evaluating the frequency of mutant variants at a threshold of

Published
2019

3. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

Author

Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, Izopet, Jacques, Lagier, E, Roussel, C, Le Guillou-Guillemette, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferré, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Defaux, A Beby-, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, and Barin, F

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Antimicrobial Resistance, Genetics, HIV/AIDS, Clinical Research, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Drug Resistance, Viral, Female, Genetic Variation, HIV Infections, HIV-1, Humans, Male, Mutation, Rilpivirine, Viral Load, minority resistant variants, rilpivirine, first-line antiretroviral therapy, ultra-deep sequencing, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundMinority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR).MethodsAll the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count

Published
2018

5. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Author

Fourati, Slim, Charpentier, Charlotte, Amiel, Corinne, Morand-Joubert, Laurence, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Nicot, Florence, Rodallec, Audrey, Maillard, Anne, Mirand, Audrey, Jeulin, Hélène, Montès, Brigitte, Barin, Francis, Bettinger, Dominique, Le Guillou-Guillemette, Hélène, Vallet, Sophie, Signori-Schmuck, Anne, Descamps, Diane, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Genevieve, Lagier, E, Roussel, C, Le Guillou, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferre, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, Costagliola, D, Allegre, T, Schmit, JL, and Chennebault, JM

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Genetics, Aetiology, 2.1 Biological and endogenous factors, Infection, Adult, Anti-HIV Agents, Drug Resistance, Viral, Female, France, HIV Infections, HIV Integrase, HIV Protease, HIV Reverse Transcriptase, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Mutant Proteins, Oxazines, Piperazines, Pyridones, Quinolones, Raltegravir Potassium, Sequence Analysis, DNA, integrase, inhibitors, mutations, patterns, ANRS AC11 Resistance Study Group, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

ObjectivesThe objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).Patients and methodsData were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23).ResultsAmong the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P

Published
2015

6. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author

Soulie, C, Descamps, D, Grude, M, Schneider, V, Trabaud, M-A, Morand-Joubert, L, Delaugerre, C, Montes, B, Barin, F, Ferre, V, Raymond, S, Jeulin, H, Alloui, C, Yerly, S, Pallier, C, Reigadas, S, Signori-Schmuck, A, Guigon, A, Fafi-Kremer, S, Haim-Boukobza, S, Mirand, A, Maillard, A, Vallet, S, Roussel, C, Assoumou, L, Calvez, V, Flandre, P, Marcelin, A-G, Lagier, E, Le Guillou, H, Bettinger, D, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vabret, A, Henquell, C, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Schvoerer, E, Andre-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Brun-Vezinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Lambert-Niclot, S, Wirden, M, Chaix, ML, Amiel, C, Giraudeau, G, Brodard, V, Plantier, JC, Chaplain, C, Bourlet, T, Stoll-Keller, F, Schmitt, MP, Barth, H, Poggi, C, Izopet, J, Chaillon, A, Marque-Juillet, S, and Roque-Afonso, AM

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, HIV/AIDS, Infectious Diseases, Antimicrobial Resistance, Genetics, Clinical Research, Neurosciences, Infection, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Nervous System Diseases, Viral Load, ANRS Resistance AC11 Group, ARV, CSF, HIV, resistance, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.

Published
2015

17. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France

Author

Cuzin, L, Yazdanpanah, Y, Huleux, T, Cotte, L, Pugliese, P, Allavena, C, Reynes, J, Poizot‐Martin, I, Bani‐Sadr, F, Delpierre, C, Brégigeon, S, Zaegel‐Faucher, O, Obry‐Roguet, V, Orticoni, M, Soavi, MJ, Luquet‐Besson, I, Ressiot, E, Carta‐Padovani, M, Ducassou, MJ, Bertone, H, Galie, S, Galinier, A, Monclar, M, Martinet, P, Ritleng, AS, Ivanova, A, Blanco‐Betancourt, C, Lions, C, Alvarez, M, Biezunski, N, Debard, A, Delobel, P, Fourcade, C, Marchou, B, Martin‐Blondel, G, Porte, L, Mularczyk, M, Garipuy, D, Saune, K, Lepain, I, Marcel, M, Puntis, E, Ceppi, C, Cua, E, Cottalorda, J, Dellamonica, P, Demonchy, E, Dunais, B, Durant, J, Etienne, C, Ferrando, S, Fuzibet, JG, Garraffo, R, Risso, K, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Pillet, S, Prouvost‐Keller, B, Pradier, C, Wehrlen‐Pugliese, S, Rosenthal, E, Sausse, S, Roger, PM, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet‐Cartier, C, Hall, N, Jovelin, T, Morineau, P, Raffi, F, Reliquet, V, Hue, H, Larmet, L, Pineau, So, Ferré, V, André‐Garnier, E, Rodallec, A, Vivrel, F, Lefebvre, M, Grossi, O, Biron, C, Point, P, Aubry, O, Cheret, A, Choisy, P, Landman, R, Duvivier, C, Valantin, MA, Agher, R, Katlama, C, Lortholary, Avettand‐Fenoel, V, Rouzioux, C, Consigny, PH, Cessot, G, Touam, F, Usubillaga, R, Benhadj, K, Cabié, A, Abel, S, Pierre‐François, S, Ouka, M, Martial, J, Rey, D, Ebel, E, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Batard, ML, Bernard‐Henry, C, e Mautort, E, Chirouze, C, Drobacheff‐Thiébaut, C, Faller, JP, Faucher, JF, Foltzer, A, Gil, H, Hustache‐Mathieu, L, Hoen, B, Jacomet, C, Laurichesse, H, Lesens, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Beytout, J, Coban, D, Casanova, S, Rouger, C, Berger, JL, NʼGuyen, Y, Lambert, D, Kmiec, I, Hentzien, M, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Ferry, T, Miailhes, P, Perpoint, T, Degroodt, S, Atoui, N, Casanova, ML, Le Moing, V, Makinson, A, Meftah, N, Merle De Boever, C, Montes, B, and Psomas, C

Published
2018
Full Text
View/download PDF

20. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

Author

Gantner, P, Cuzin, L, Allavena, C, Cabie, A, Pugliese, P, Valantin, M‐A, Bani‐Sadr, F, Joly, V, Ferry, T, Poizot‐Martin, I, Garraffo, R, Peytavin, G, Fafi‐Kremer, S, Rey, D, Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet, C., Jovelin, T., Hall, N., Bernaud, C., Morineau, P., Reliquet, V., Aubry, O., Point, P., Besnier, M., Grossi, O., Lefebvre, M., Hüe, H., Cavellec, M., Soria, A., Pineau, S., André‐Garnier, E., Rodallec, A., Brégigeon, S., Faucher, O., Obry‐Roguet, V., Orticoni, M., Soavi, M. J., Luquet‐Besson, I., Ressiot, E., Pinot, I., Ducassou, M. J., Bertone, H., Gallie, S., Trijau, S., Ritleng, A. S., Ivanova, A., Guignard, M., Blanco‐Betancourt, C., Alvarez, M., Biezunski, N., Debard, A., Delobel, P., Delpierre, C., Fourcade, C., Marchou, B., Martin‐Blondel, G., Porte, L., Mularczyk, M., Garipuy, D., Saune, K., Lepain, I., Marcel, M., Puntis, E., Ceppi, C., Cua, E., Cottalorda, J., Dellamonica, P., Demonchy, E., Dunais, B., Durant, J., Etienne, C., Ferrando, S., Fuzibet, J. G., Risso, K., Mondain, V., Naqvi, A., Oran, N., Perbost, I., Pillet, S., Prouvost‐Keller, B., Pradier, C., Wehrlen‐Pugliese, S., Rosenthal, E., Sausse, S., Roger, P. M., Choisy, Ph., Vandame, S., Huleux, Th., Ajana, F., Alcaraz, I., Baclet, V., Huleux, T. H., Melliez, H., Viget, N., Valette, M., Aissi, E., Allienne, Ch., Meybeck, A., Riff, B., Agher, R., Katlama, C., Duvivier, C., Yazdanpanah, Y., Landman, R., Mackoumbou‐Nkouka, C., Louni, F., Julia, Z., Charpentier, C., Descamps, D., Cotte, L., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I., Dahoud, F., Lippmann, J., Braun, E., Koffi, J., Longuet, C., Guéripel, V., Augustin‐Normand, C., Degroodt, S., Batard, M. L., Bernard‐Henry, C., Cheneau, C., de Mautort, E., Fischer, P., Partisani, M., Priester, M., Bani‐Sadr, F., Rouger, C., Berger, J. L., NʼGuyen, Y., Lambert, D., Kmiec, I., Hentzien, M., and Lebrun, D.

Published
2017
Full Text
View/download PDF

23. Recent occurrences of opah, Lampris guttatus (Actinopterygii, Lampriformes, Lampridae), in the western Mediterranean Sea

Author

P. Francour, M. Cottalorda J., M. Aubert, S. Bava, M. Colombey, P. Gilles, H. Kara, P. Lelong, L. Mangialajo, R. Miniconi, and P. Quignard J.

Subjects
new records, first record, Algeria, Mediterranean, Aquaculture. Fisheries. Angling, SH1-691
Abstract

The first records of Lampris guttatus in the Mediterranean Sea date back to 1807. Yet, until now it has been considered as a rare species (less than 25 specimens recorded in the literature). Since 2008, at least 23 specimens have been fished or observed along the French Mediterranean coast. In this paper, we present an updated review of records in the Mediterranean and discuss the possible link with the present sea water warming. We hypothesise that the recent Mediterranean specimens could come from the Atlantic, throughout the Gibraltar Strait, following a northward migration along the Northeast Atlantic coast due to present global warming.

Published
2010
Full Text
View/download PDF

24. Spinal Trauma in Children

Author

Bollini, Gerard, Jouve, J. L., Cottalorda, J., Holtzman, Robert N. N., editor, McCormick, Paul C., editor, Farcy, Jean-Pierre C., editor, and Winston, Heidi, editor

Published
1993
Full Text
View/download PDF

28. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

Author

Frange, Pierre, Assoumou, Lambert, Descamps, Diane, Chéret, Antoine, Goujard, Cécile, Tran, Laurent, Gousset, Marine, Avettand-Fenoël, Veronique, Bocket, Laurence, Fafi-Kremer, Samira, Guinard, Jerome, Morand-Joubert, Laurence, Nicot, Florence, Plantier, Jean-Christophe, Rogez, Sylvie, Wirden, Marc, Rouzioux, Christine, Meyer, Laurence, Chaix, Marie-Laure, Abel, S., Abraham, B., Allegre, T., Antoniotti, A., Armero, R., Audhuy, B., Aumaitre, H., Beaucaire, G., Beck-Wirth, G., Berger, J.L., Bernard, L., Beuscart, C., Bodard, L., Bouchaud, O., Boué, F., Cabane, J.-P., Cabie, A., Champagne, H., Cheneau, C., Chennebault, J.-M., Cheret, A., Christian, B., Compagnucci, A., Daneluzzi, V., Debab, Y., Dellamonica, P., Delfraissy, J.-F., Devidas, A., Diab, G., Doll, J., Drobacheff-Thebaut, M.C., Durel, A., Duvivier, C., Esnault, J.-L., Faba, L., Froguel, E., Garipuy, D., Garrait, V., Geffray, L., Genet, C., Genet, P., Gerard, L., Ghosn, J., Girard, J-.J., Girard, P.-M., Godin-Collet, C., Hochedez, P., Hoen, B., Houlbert, D., Jacomet, C., Jeantils, V., Jidar, K., Katlama, C., Klement, E., Lafeuillade, A., Lascoux, C., Launay, V., Lepretre, A., Levy, Y., Makhloufi, D., Malbec, D., Martha, B., May, T., Merrien, D., Miailhes, P., Miodovski, C., Molina, J.-M., Morlat, P., Mortier, E., Neau, D., Obadia, M., Patey, O., Pellegrin, J.-L., Perronne, V., Philibert, P., Pialoux, G., Pichancourt, G., Piroth, L., Poinsignon, Y., Poizot-Martin, I., Prazuck, T., Prendki, V., du Clary, F. Preveteau, Quinsat, D., Raffi, F., Regnier, A., Reynes, J., Rosenthal, E., Rouveix, E., Salmon, D., Salanville, F., Schmitt, J.-L., Simon-Coutellier, A., Sotto, A., Souala, F., Stein, A., Timsit, F., de Truchis, P., Uludag, A., Vaillant, O., Verdon, R., Verlesch-Langlin, A., Viard, J.-P., Vittecoq, D., Weiss, L., Yéni, P., Zucman, D., Allavena, C., Allegre, T., Amri, I., Autran, B., Bacchus, C., Blanc, C., Bonne, S., Bonnet, B., Bouchez, S., Charlier, C., Consigny, P.-H., Duvivier, C., Fourn, E., Guiroy, F., Huleux, T., Katlama, C., Lascoux-Combe, C., Leplatois, A., Lyavanc, T., Molina, J.-M., Naqvi, A., Nembot, G., Quertainmont, Y., Raffi, F., Samri, A., Schneider, L., Seang, S., Seksik, B.C.P., Shoai-Tehrani, M., Slama, L., Valentin, M.-A., Yazdanpanah, Y., Alloui, C., Amiel, C., André, P., André-Garnier, E., Anies, G., Barin, F., Bellecave, P., Bettinger, D., Bouvier-Alias, M., Brun-Vézinet, F., Calmy, A., Calvez, V., Caveng, W., Chaillon, A., Chapalay, S., Charpentier, C., Costagliola, D., Cottalorda, J., Delamare, C., Delaugerre, C., Dina, J., Santos, G. Dos, Férré, V., Flandre, P., Fleury, H., Fourati, S., Gaille, C., Giraudeau, G., Guigon, A., Haim-Boukobza, S., Lagier, E., Le Guillou-Guillemette, H., Henquell, C., Izopet, J., Lambert-Niclot, S., Leroux, M., Maillard, A., Malet, I., Marcelin, A.-G., Marque-Juillet, S., Masquelier, B., Mirand, A., Morand, P., Montes, B., Mouna, L., Noel, C., Pallier, C., Peytavin, G., Pinson-Recordon, P., Poveda, J.D., Raymond, S., Reigadas, S., Roques, A.-M., de Rougemont, A., Roussel, C., Schmitt, M.-P., Schneider, V., Schvoerer, E., Signori-Schmuck, A., Soulié, C., Tamalet, C., Tardy, J.C., Trabaud, M.-A., Vabret, A., Vallet, S., and Yerly, S.

Published
2015
Full Text
View/download PDF

33. Traitement des Dystrophies Rachidiennes de Croissance (DRC) dans sa forme commune

Author

DELPONT, M., JOLY MONRIGAL, P., NEAGOE, P., LOUAHEM, D., JEANDEL, C., ALKAR, F., PATTE, K., and COTTALORDA, J.

Subjects
Scheuermann, adolescent, rééducation
Abstract

Holger Werfel Scheuermann, médecin suédois, a décrit en 1920, une hypercyphose thoracique douloureuse de l’adolescent qu’il a rapprochée de la « cyphose de apprentis » décrite elle-même en 1891 par Schanz. La « maladie de Scheuermann » est une maladie de la croissance des corps vertébraux. Elle correspond à une Dystrophie Rachidienne de Croissance : DRC, terminologie que nous utiliserons dans ce chapitre. La prévalence de cette maladie dans la population générale diffère selon les publications entre 2 et 10 %. Ces chiffres sont souvent calculés pour les DRC de forme typique, ce qui les sous-estime. Certaines études montrent qu’elle est plus élevée chez les hommes que chez les femmes.

Published
2020
Full Text
View/download PDF

37. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011

Author

Descamps, Diane, Assoumou, Lambert, Chaix, Marie-Laure, Chaillon, Antoine, Pakianather, Sophie, de Rougemont, Alexis, Storto, Alexandre, Dos Santos, Georges, Krivine, Anne, Delaugerre, Constance, Montes, Brigitte, Izopet, Jacques, Charpentier, Charlotte, Wirden, Marc, Maillard, Anne, Morand-Joubert, Laurence, Pallier, Coralie, Plantier, Jean-Christophe, Guinard, Jérôme, Tamalet, Catherine, Cottalorda, Jacqueline, Marcelin, Anne-Geneviève, Desbois, Delphine, Henquell, Cecile, Calvez, Vincent, Brun-Vézinet, Françoise, Masquelier, Bernard, Costagliola, Dominique, Lagier, E., Roussel, C., Le Guillou-Guillemette, H., Alloui, C., Bettinger, D., Anies, G., Reigadas, S., Bellecave, P., Pinson-Recordon, P., Fleury, H., Masquelier, B., Vallet, S., Leroux, M., Dina, J., Vabret, A., Poveda, J. D., Mirand, A., Henquell, C., Bouvier-Alias, M., Noel, C., De Rougemont, A., Dos Santos, G., Yerly, S., Gaille, C., Caveng, W., Chapalay, S., Calmy, A., Signori-Schmuck, A., Morand, P., Pallier, C., Bocket, L., Mouna, L., Ranger-Rogez, S., André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Delamare, C., Montes, B., Schvoerer, E., André-Garnier, E., Férré, V., Cottalorda, J., Guigon, A., Guinard, J., Descamps, D., Charpentier, C., Peytavin, G., Brun-Vézinet, F., Haim-Boukobza, S., Roques, A. M., Soulié, C., Lambert-Niclot, S., Malet, I., Wirden, M., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Assoumou, L., Costagliola, D., Morand-Joubert, L., Delaugerre, C., Schneider, V., Amiel, C., Giraudeau, G., Maillard, A., Plantier, J. C., Fafi-Kremer, S., Schmitt, M. P., Raymond, S., Izopet, J., Chaillon, A., Barin, F., and Marque Juillet, S.

Published
2013
Full Text
View/download PDF

41. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism

Author

Raymond, Stéphanie, Recordon-Pinson, Patricia, Saliou, Adrien, Delobel, Pierre, Nicot, Florence, Descamps, Diane, Marcelin, Anne-Geneviève, Flandre, Philippe, Calvez, Vincent, Masquelier, Bernard, Izopet, Jacques, Recordon-Pinson, P., Fleury, H., Masquelier, B., Vabret, A., Pallier, C., Lazrek, M, André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Montes, B., Segondy, M., Ferré, V., Cottalorda, J., Macé, M., Descamps, D., Brun-Vézinet, F., Si-Mohammed, A., Charpentier, C., Desbois, D., Dussaix, E., Marcelin, A. G., Soulié, C., Calvez, V., Flandre, F., Morand-Joubert, L., Amiel, C., Schneider, V., Maillard, A., Ruffault, A., Izopet, J., Nicot, F., Delobel, P., and Raymond, S.

Published
2011
Full Text
View/download PDF

44. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France

Author

Descamps, Diane, Chaix, Marie-Laure, Montes, Brigitte, Pakianather, Sophie, Charpentier, Charlotte, Storto, Alexandre, Barin, Francis, Dos Santos, Georges, Krivine, Anne, Delaugerre, Constance, Izopet, Jacques, Marcelin, Anne-Geneviève, Maillard, Anne, Morand-Joubert, Laurence, Pallier, Coralie, Plantier, Jean-Christophe, Tamalet, Catherine, Cottalorda, Jacqueline, Desbois, Delphine, Calvez, Vincent, Brun-Vezinet, Françoise, Masquelier, Bernard, Costagliola, Dominique, Alloui, C., Bettinger, D., Anies, G., Masquelier, B., Vallet, S., Henquell, C., Bouvier-Alias, M., DosSantos, G., Signori-Schmuck, A., Rogez, S., André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Montes, B., Cottalorda, J., Descamps, D., Brun-Vézinet, F., Charpentier, C., Chaix, M. L., Desbois, D., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Morand-Joubert, L., Delaugerre, C., Ruffault, A., Maillard, A., Plantier, J. C., Bourlet, T., Saoudin, H., Izopet, J., and Barin, F.

Published
2010
Full Text
View/download PDF

48. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

Author

Cuzin, Lise, Pugliese, Pascal, Katlama, Christine, Bani-Sadr, Firouzé, Ferry, Tristan, Rey, David, Lourenco, Jeremy, Bregigeon, Sylvie, Allavena, Clotilde, Reynes, Jacques, Cabié, André, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache-Mathieu, L, Chirouze, C, Lepiller, Q, Bozon, F, Babre, O, Muret, P, Laurichesse, H, Lesens, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Letertre, P, Casanova, S, Jacomet, C, Hoen, B, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Miailhes, P, Perpoint, T, Roux, S, Degroodt, S, Brochier, C, Valour, F, Chidiac, C, Dhiver, C, Mokhtari, M Saadia, Ménard, A, Dupont, H Tissot, Toméi, C, Meddeb, L, Belkhir, A, Ravaux, I, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Orticoni, M, Soavi, M, Luquet-Besson, I, Ressiot, E, Carta-Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A, Monclar, M, Ritleng, A, Ivanova, A, Blanco-Betancourt, C, Lions, C, Poizot-Martin, I, Abel, S, Césaire, R, Cuzin, L, Santos, G Dos, Fagour, L, Illiaquer, M, Najioullah, F, Nguyen, D, Ouka, M, Pierre-François, S, Pasquier, J, Pircher, M, Rozé, B, Cabié, A, Atoui, N, Moing, V Le, Makinson, A, Meftah, N, de Boever, C Merle, Montes, B, Ferrer, a Montoya, Reynes, J, André, M, Boyer, L, Bouillon, M, Delestan, M, May, T, Allavena, C, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Hall, N, Jovelin, T, Morineau, P, Reliquet, V, Hue, H, Sécher, S, Cavellec, M, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Guen, L Le, Lefebvre, M, Grossi, O, Point, P, Aubry, O, Khatchatourian, L, Raffi, F, Pugliese, P, Breaud, S, Ceppi, C, Courjon, J, Cua, E, Cottalorda, J, Dellamonica, P, Demonchy, E, Monte, a De, Durant, J, Etienne, C, Ferrando, S, Fuzibet, J, Garraffo, R, Joulie, A, Risso, K, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Pillet, S, Prouvost-Keller, B, Pradier, C, Wehrlen-Pugliese, S, Rio, V, Rosenthal, E, Sausse, S, Zouzou, G, Hocqueloux, L, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Vittecoq, D, Deradji, O, Fourreau, F, Pallier, C, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C, Lariven, S, Gervais, A, Lescure, F, Matheron, S, Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, C, Descamps, D, Peytavin, G, Yazdanpanah, Y, Consigny, P, Cessot, G, Bossi, P, Goesch, J, Gilquin, J, Benabdelmoumen, G, Lanternier, F, Charlier, C, Amazzough, K, Henry, B, Pilmis, B, Rouzaud, C, Morgand, M, Touam, F, Louisin, C, Duvivier, C, Lortholary, O, Guery, R, Danion, F, Lourenco, J, Parize, P, Etienne, N, Launay, M, Rouzioux, C, Avettand Fenoel, V, Valantin, M, Flandre, P, Caby, F, Tubiana, R, Agher, R, Seang, Sophie, Schneider, L, Palich, R, Blanc, C, Katlama, C, Berger, J, N’guyen, Y, Lambert, D, Lebrun, D, Kmiec, I, Hentzien, M, Brodard, V, Bani-Sadr, F, Botelho-Nevers, E, Gagneux-Brunon, A, Frésard, A, Lucht, F, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Rey, D, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Lansalot, P, Lelièvre, L, Martin-Blondel, G, Metsu, D, Piffaut, M, Porte, L, Saune, K, Delobel, P, Ajana, F, Alcaraz, I, Baclet, V, Boucher, A, Choisy, P, Huleux, T, Lafon-Desmurs, B, Melliez, H, Meybeck, A, Pasquet, A, Pradier, M, Robineau, O, Viget, N, Valette, M, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Service de Maladies Infectieuses et Tropicales, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Maladies Infectieuses [Nice], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Reims (CHU Reims), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), CHU Strasbourg, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Istituto Nazionale di Fisica Nucleare [Sezione di Roma 1] (INFN), Istituto Nazionale di Fisica Nucleare, Service d'immuno-hématologie clinique (CISIH), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance Publique - Hôpitaux de Marseille (APHM), Clinique Pasteur [Toulouse], Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), DDSIS 76, Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), CHU Fort de France, Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, CHU Fort de France-CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France], Cliniques Universitaires UCL Mont-Godinne, CHU Pontchaillou [Rennes], Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), Service des maladies infectieuses et tropicales [CHU Nantes], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Chercheur indépendant, Service de chirurgie pédiatrique [Hôpital Lapeyronie-Arnaud de Villeneuve], Hôpital Lapeyronie [Montpellier] (CHU), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Evelina London Children's Hospital, Hôpital Bicêtre, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service de Maladies Infectieuses et Tropicales [CHU Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Registre EPIMAD, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Centre d'infectiologie Necker-Pasteur [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Service des Maladies infectieuses et tropicales [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Laboratoire de Virologie [CHU Necker], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Etienne, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Centre Hospitalier Tourcoing, CHU de Fort de France, Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Laboratoire Chrono-environnement (UMR 6249) (LCE), Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance Publique-Hôpitaux de Marseille (AP-HM), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD [France-Sud]), Université de Montpellier (UM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Médecine interne, Maladies Infectieuses et Immunologie Clinique [Reims], Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], and Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière]

Subjects
Male, 0301 basic medicine, [SDV]Life Sciences [q-bio], Integrase inhibitor, HIV Infections, Quinolones, Piperazines, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Abacavir, Antiretroviral Therapy, Highly Active, Public Health Surveillance, Pharmacology (medical), Prospective Studies, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Antiinfective agent, Elvitegravir, Mental Disorders, Cobicistat, Viral Load, 3. Good health, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Dolutegravir, Female, France, Heterocyclic Compounds, 3-Ring, medicine.drug, Microbiology (medical), medicine.medical_specialty, Pyridones, 030106 microbiology, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Raltegravir Potassium, Internal medicine, Oxazines, medicine, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, HIV Integrase Inhibitors, Pharmacology, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Raltegravir, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, CD4 Lymphocyte Count, Discontinuation, chemistry, Nervous System Diseases, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

OBJECTIVES To analyse the frequency and causes of treatment discontinuation in patients who were treated with an integrase strand transfer inhibitor (INSTI), with a focus on neuropsychiatric adverse events (NPAEs). METHODS Patients in 18 HIV reference centres in France were prospectively included in the Dat'AIDS cohort. Data were collected from all patients starting an INSTI-containing regimen between 1 January 2006 and 31 December 2016. All causes of INSTI-containing regimen discontinuations were analysed, and patients' characteristics related to discontinuation due to NPAEs were sought. RESULTS INSTIs were prescribed to 21315 patients: 6274 received dolutegravir, 3421 received elvitegravir boosted by cobicistat, and 11620 received raltegravir. Discontinuation was observed in 12.5%, 20.2% and 50.9% of the dolutegravir-, elvitegravir- and raltegravir-treated patients, respectively (P

Published
2019

49. Median Nerve Entrapment after Supracondylar Humeral Fracture in a Young Child

Author

Granier, C., Maury, E., Coulet, B., Delpont, M., Cottalorda, J., Sleth, C., Carré, R., and Louahem, D.

Subjects
Article Subject
Abstract

Median nerve entrapment after supracondylar humeral fracture in children is rare. We report a case of Gartland type III supracondylar humeral fracture complicated by an entrapment of the median nerve following closed reduction and percutaneous pinning in a 5-year-old child. The diagnosis of entrapment was made 14 months post injury following progressive motor and sensory palsy. Resection and end-to-end suture were performed, leading to complete sensory and motor recovery eight months later. This nerve complication is often unnoticed and should be suspected systematically before and after reduction of all displaced supracondylar humeral fracture in children. The indication of resection-suture or nerve graft depends on the entrapment and the delay of the palsy.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results